The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Oct. 20, 2016
Applicant:

Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;

Inventors:

Sara Frattini, Castelleone, IT;

Remko Bakker, Biberach an der Riss, DE;

Riccardo Giovannini, Biberach an der Riss, DE;

Dieter Hamprecht, Frenchs Forest, AU;

Iain Lingard, Monza, IT;

Alexander Pautsch, Biberach an der Riss, DE;

Bernd Wellenzohn, Friedrichshafen, DE;

Assignee:

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 403/12 (2006.01); A61K 31/444 (2006.01); A61K 31/4709 (2006.01); A61K 31/438 (2006.01); A61K 45/06 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/438 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 45/06 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01);
Abstract

The present invention relates to compounds of general formula I, wherein Dto D, A, R, R, Y and n are defined as in claim, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.


Find Patent Forward Citations

Loading…